Courtagen Developing Assay for Avaxia's Radiation Therapy | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protein diagnostic firm Courtagen said today that it has entered into a collaboration with Avaxia Biologics to create an assay for use in developing an oral antibody therapy to mitigate the gastrointestinal damage caused by radiation exposure.

The therapy being developed is for use in radiation exposure from a nuclear incident.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.